Day: March 7, 2024

<div>Aterian Makes Strategic Minority Equity Investment in 4th & Heart</div>

Aterian Makes Strategic Minority Equity Investment in 4th & Heart

4th & Heart is the #1 Ghee Butter Brand in the US NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”) today announced the recent closing of a strategic minority equity investment in 4th & Heart, the leading U.S. maker of premium ghee butter products. The Company invested approximately $0.2 million in cash and approximately 145,000 shares of Aterian common stock. No other terms of the transaction were disclosed. “We are excited to announce our participation in 4th & Heart’s funding round and we look forward to exploring potential strategic opportunities between our two companies,” said Joe Risico, Aterian’s Co-CEO. “Like our Squatty Potty brand, we see a lot of value in partnering and investing in brands that offer consumers the opportunity to live a healthier,...

Continue reading

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company’s independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consists of a non-qualified stock option to purchase an aggregate of 30,000 shares of the Company’s common stock with a 10-year term and an exercise price of $25.75 per share. The option vests as to 25%...

Continue reading

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

BOSTON, March 07, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings. A live webcast and replay of the presentation will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently...

Continue reading

Golden Star Filed Supplement to Proxy Statement

Golden Star Filed Supplement to Proxy Statement

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — Golden Star Acquisition Corporation (NASDAQ: GODN) (the “Company” or “Golden Star”) announced today that, on March 6, 2024, it filed a supplement (the “Supplement”) to the definitive proxy statement dated February 7, 2024 (together with the additional proxy statement supplements and annexes, the “Proxy Statement”) with the U.S. Securities and Exchange Commission (the “Commission”), to amend the monthly fee payable by the sponsor of the Company and/or its designee into the trust account to extend the date by which the Company must consummate its initial business combination as proposed in the original Proposal 1 to the extraordinary general meeting of shareholders to be held originally on February 27, 2024, from an amount equal to the lesser of (i) $50,000 for all outstanding Public Shares...

Continue reading

FAT BRANDS INC. REPORTS FISCAL FOURTH QUARTER AND FULL FISCAL YEAR 2023 FINANCIAL RESULTS

FAT BRANDS INC. REPORTS FISCAL FOURTH QUARTER AND FULL FISCAL YEAR 2023 FINANCIAL RESULTS

Conference call and webcast today at 5:00 p.m. ET LOS ANGELES, March 07, 2024 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”) today reported fiscal fourth quarter and full fiscal year 2023 financial results for the fiscal year ended December 31, 2023. “With the acquisition of Smokey Bones early in the fourth quarter, we have grown the FAT Brands portfolio to 18 iconic restaurant brands with annualized system wide sales of $2.5 billion,” said Andy Wiederhorn, Chairman of FAT Brands. “We opened 125 restaurants in 2023, including 29 in the fourth quarter. We are seeing strong franchisee interest in development opportunities, having signed more than 225 development agreements in 2023, bringing our total pipeline to 1,100 units. This represents the potential for over 50% EBITDA...

Continue reading

Bel Director John Tweedy to Retire from the Board and Not Stand for Re-election at the 2024 Annual Meeting

Bel Director John Tweedy to Retire from the Board and Not Stand for Re-election at the 2024 Annual Meeting

Bel plans to nominate David Valletta to join the Board, Former Executive Vice President of Worldwide Sales at Vishay Intertechnology WEST ORANGE, N.J., March 07, 2024 (GLOBE NEWSWIRE) — Bel Fuse Inc. (Nasdaq: BELFA and BELFB) (“Bel” or the “Company”), a designer, manufacturer, and provider of products that power, protect and connect electronic circuits, today announced that John Tweedy will retire from the Board and not stand for re-election at the Company’s 2024 Annual Meeting of Shareholders. The Board of Directors plans to nominate David Valletta to join the Board in 2024. Mr. Tweedy has served on Bel’s Board since 1996 and throughout the years has served on various committees including Audit and Executive. John has been instrumental during Bel’s various acquisitions, international expansion, and recent changes to the overall...

Continue reading

Progress Announces Amended Credit Facility

Progress Announces Amended Credit Facility

New $900M facility provides liquidity and flexibility at greater scale BURLINGTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) —  Progress (NASDAQ: PRGS), the trusted provider of infrastructure software, today announced that it has entered into a Fourth Amended and Restated Credit Agreement (the “Amended Credit Agreement”), which provides a revolving credit facility in an aggregate principal amount of $900 million, and replaces the Company’s existing secured credit facilities. The revolving facilities under the Amended Credit Agreement will mature on March 7, 2029. As of the closing date, the Amended Credit Agreement has no term loan facility and there are no revolving credit loans outstanding.   Progress CFO Anthony Folger stated, “This new credit facility provides more scale and flexibility, both of which are important to support...

Continue reading

The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results

The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results

– Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 – – Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program – SCOTTSDALE, Ariz., March 07, 2024 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter and year ended December 31, 2023. Financial Highlights: Q4 2023 Compared to Q4 2022 Grew revenue 11% to $30.6 million. Recorded net loss on disposition or impairment of $1.5 million, compared to $50,000. Recorded operating loss of $147,000, compared to operating income of $1.5 million. Recorded non-cash valuation allowance against deferred tax assets of $10.8 million. Reported net loss, including the non-cash valuation allowance, of...

Continue reading

NCS Multistage Holdings, Inc. Announces Fourth Quarter and Full Year 2023 Results

NCS Multistage Holdings, Inc. Announces Fourth Quarter and Full Year 2023 Results

Fourth Quarter Results Total revenues of $35.2 million, compared to $40.2 million in 2022 Net income of $39.6 million and earnings per diluted share of $15.80, benefited by a legal settlement, compared to $2.0 million and earnings per diluted share of $0.81 for the fourth quarter of 2022 Adjusted net loss of $(0.9) million and adjusted loss per share of $(0.36), compared to adjusted net income of $1.8 million and adjusted earnings per diluted share of $0.75 in the fourth quarter of 2022 Adjusted EBITDA of $2.5 million, compared to $6.4 million in the fourth quarter of 2022 Full Year Results Total revenues of $142.5 million, compared to $155.6 million in 2022 Net loss of $(3.2) million and a loss per share of $(1.27), compared to a net loss of $(1.1) million and a loss per share of $(0.45) in 2022 Adjusted net loss of $(1.3) million...

Continue reading

Clarus Reports Fourth Quarter and Full Year 2023 Results

Clarus Reports Fourth Quarter and Full Year 2023 Results

Adventure Segment Generates Highest Quarterly Revenue of the Year Proceeds from Precision Sport Sale Used to Repay All Debt and Significantly Increased Cash Position Positioning Company for Growth and Profitability in 2024 and Beyond as a Pure-Play Outdoor Business SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Summary vs. Same Year‐Ago Quarter (adjusted to reflect the reclassification of the Precision Sport segment as discontinued operations) Sales of $76.5 million compared to $73.8 million. Gross margin was 28.9% compared to 37.2%. Loss from continuing operations of $7.2 million,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.